RxDoctor Payments Data

John Djabrayan, MD

Family Medicine · Fresno, CANPI 1861805814

Payments from drug & device makers

$1,795in general payments, 2019–2025

Across 96 payments — averaging $18.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$436
  • Pfizer$229
  • Exact Sciences$179
  • Merck$147
  • Novo Nordisk$95
  • Amgen$85
  • plus $625 from 21 others

What the payments were for

  • Food & beverage$1,795100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,795 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$1,742
Medicare patients
40
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide83$115,202
JardianceEmpagliflozin81$68,005
OzempicSemaglutide50$64,144
RybelsusSemaglutide32$30,945
MounjaroTirzepatide17$28,203
EliquisApixaban32$18,993
Nurtec OdtRimegepant Sulfate13$18,726
JanuviaSitagliptin Phosphate11$11,928
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$9,506
VascepaIcosapent Ethyl22$8,652
Repatha SureclickEvolocumab15$8,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,137
SynjardyEmpagliflozin/Metformin Hcl11$5,247
Lidocaine42$4,876
MyrbetriqMirabegron11$4,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$436$143,405100 claims
Novo NordiskOzempic, Rybelsus$95$95,08982 claims
Boehringer IngelheimJardiance, Synjardy$17$73,25292 claims
PfizerEliquis, Nurtec Odt$229$37,72045 claims
MerckJanuvia$147$11,92811 claims
GSKTrelegy Ellipta$38$7,13712 claims
Astellas Pharma US IncMyrbetriq$37$4,47811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →